Skip to content Skip to navigation

Recent News

Since its founding 50 years ago, only three executive directors have helmed Stanford’s tech transfer office. They sit down to talk leadership, “secret sauces,” and mission.
Jan 8 2021 | Endpoints News
Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half. On Friday, those big plans landed him an $80 million Series C round...
Dec 14 2020 | BUSINESS WIRE
- IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene editing therapy to restore normal hemoglobin expression - GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms to precisely insert the correct DNA...
Sep 18 2020 | Posted In: Announcements
Ten world-leading US, UK, and EU universities will discuss with leaders in national government and funding bodies on how to harness the enormous potential of research and commercialization for the urgent economic recovery in the wake of the COVID-19 pandemic. University researchers contributed to...
Sep 17 2020 | Endpoints News | Posted In: In the News
When Jim Broderick launched Massachusetts-based Palleon Pharmaceuticals in 2015, he had an office in Cambridge’s Kendall Square, a bit of seed money, and a blank canvas. He set out to innovate within a new space in immunology, and recruited scientific co-founders Carolyn Bertozzi, a Stanford...

Pages